Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China

Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China

Abstract Background Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high risk of virological relapse after discontinuation. The combined therapy of NAs plus...

Full description

Bibliographic Details
Main Authors: Xiaoke Li, Ludan Zhang, Mei Qiu, Yi Huang, Huanming Xiao, Bingjiu Lu, Yuyong Jiang, Fuli Long, Hui Lin, Jinyu He, Qikai Wu, Mingxiang Zhang, Li Wang, Xiaoning Zhu, Man Gong, Xuehua Sun, Jianguang Sun, Fengxia Sun, Wei Lu, Weihua Xu, Guang Chen, Zhiguo Li, Danan Gan, Xianzhao Yang, Hongbo Du, Yong’an Ye
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Trials
Subjects:
Chronic hepatitis B
Chinese herbal medicine formula
Protocol
Randomized-controlled trial
Online Access:http://link.springer.com/article/10.1186/s13063-020-04417-9

Internet

http://link.springer.com/article/10.1186/s13063-020-04417-9

Similar Items